Stereotaxis

Stereotaxis Reports 2023 Third Quarter Financial Results

Retrieved on: 
Thursday, November 9, 2023
Average cost, Abbott, Operating cost, NYSE, International, Genesis, Physician, MicroPort, Growth, Ecosystem, Magic, Patient, Robotics, Pharmaceutical industry, Video game, Stereotaxis

ST. LOUIS, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the third quarter ended September 30, 2023.

Key Points: 
  • ST. LOUIS, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the third quarter ended September 30, 2023.
  • “Stereotaxis continues to deliver commercial results and advance a robust innovation strategy, while maintaining financial discipline,” said David Fischel, Chairman and CEO.
  • At September 30, 2023, Stereotaxis had cash and cash equivalents, including restricted cash, of $23.0 million and no debt.
  • Stereotaxis will host a conference call and webcast today, November 9, 2023, at 10:00 a.m. Eastern Time.

Abbott and Stereotaxis Technologies Used in First Integrated Procedures in the United States

Retrieved on: 
Tuesday, October 31, 2023
Associate, NYSE, Cardiac electrophysiology, Overland Park Regional Medical Center, Robotics, Physician, Icahn School of Medicine at Mount Sinai, Electrophysiology, Arrhythmia, Banner - University Medical Center Phoenix, Weill Cornell Medical Center, Heart Rhythm, Workflow, Patient, Diagnosis, Medical device, Stereotaxis, Medicine

ST. LOUIS, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the first patients in the United States have been treated successfully utilizing Abbott’s EnSite™ X EP System integrated with Stereotaxis’ Robotic Magnetic Navigation System.

Key Points: 
  • ST. LOUIS, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the first patients in the United States have been treated successfully utilizing Abbott’s EnSite™ X EP System integrated with Stereotaxis’ Robotic Magnetic Navigation System.
  • The integration of Abbott’s leading cardiac mapping system and Stereotaxis’ advanced robotic technology, first announced at Heart Rhythm 2023, combines highly detailed real-time diagnostic information with the unprecedented precision and stability of robotics during therapy delivery.
  • The first integrated procedures in the US were completed by physicians at Weill Cornell Medical Center, Mount Sinai Morningside, Banner University Medical Center Phoenix, and Overland Park Regional Medical Center.
  • “The combined benefits of advanced mapping and robotic technologies allows us to envision a new era of cardiac care where personalized therapy is designed and delivered to each individual patient.

Stereotaxis Robotic Technology to be Featured during 7th Annual Meeting of the Society for Cardiac Robotic Navigation

Retrieved on: 
Wednesday, October 4, 2023
Learning, Society, Physician, Faculty, Cardiology, Robotics, FDA, Intuitive Surgical, Big Tech, NYSE, Medical device, Stereotaxis

The global physician-led Society for Cardiac Robotic Navigation (SCRN) is dedicated to establishing a community and platform for users of robotic technologies in cardiology.

Key Points: 
  • The global physician-led Society for Cardiac Robotic Navigation (SCRN) is dedicated to establishing a community and platform for users of robotic technologies in cardiology.
  • The annual SCRN conference provides a venue for physicians and healthcare professionals to share best practices, discuss new clinical literature, and evaluate the latest innovations in technology.
  • “It is exciting to see the growing momentum of robotics reflected in the expansion of the strong, physician-led Society for Cardiac Robotic Navigation,” said David Fischel, Stereotaxis Chairman and CEO.
  • “We look forward to learning from and connecting with the physicians and industry partners at the conference.”

Heart Centre Rigshospitalet Enhances Leadership in Patient Care with Adoption of Latest Robotic Technology

Retrieved on: 
Wednesday, September 6, 2023
Partnership, Copenhagen University Hospital, Heart failure, Arrest, Stroke, Genesis, Arrhythmia, Robotic magnetic navigation, Hospital, Patient, Physician, Risk, Rigshospitalet, Health, NYSE, Shahid Gangalal National Heart Centre, Safety, Electrophysiology, Medical device, Nursing, Stereotaxis

The Genesis system is the latest and most advanced robotic technology available for the treatment of heart rhythm disorders.

Key Points: 
  • The Genesis system is the latest and most advanced robotic technology available for the treatment of heart rhythm disorders.
  • Electrophysiologists at The Heart Centre Rigshospitalet were early pioneers, and are global leaders, in the use of advanced robot technology for the treatment of cardiac arrhythmias.
  • Since installation of the first robotic system in 2006, Rigshospitalet physicians have successfully treated over 5,000 patients using Stereotaxis’ robotic technology.
  • “We look forward to continuing a strong collaboration that advances patient care, clinical science, and technology development in electrophysiology.”

Live Long-Distance TeleRobotic Procedures to Highlight Stereotaxis Technology at Asia Pacific Heart Rhythm Symposium

Retrieved on: 
Wednesday, August 16, 2023
Cardiac cycle, Society, Atrial fibrillation, Hospital, MicroPort, Patient, Physician, Electrophysiology, Diagnosis, Cardiology, Congress, Robotics, NYSE, Medical device, Stereotaxis, EP

ST. LOUIS, Aug. 16, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that its technology will be the focus of multiple live long-distance telerobotic procedures at the upcoming Asia Pacific Heart Rhythm Society (APHRS) Scientific Sessions.

Key Points: 
  • ST. LOUIS, Aug. 16, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that its technology will be the focus of multiple live long-distance telerobotic procedures at the upcoming Asia Pacific Heart Rhythm Society (APHRS) Scientific Sessions.
  • APHRS and the Society for Cardiac Robotic Navigation will host a joint session on September 2, 2023, during the APHRS annual congress.
  • APHRS is the first society organized in the Asia Pacific region to promote excellence and advancement in the diagnosis and treatment of patients with heart rhythm disease.
  • They provide a platform for professional education, sharing of cutting-edge science, demonstration of advanced and novel techniques, and interaction among international experts in the field of heart rhythm management.

Stereotaxis Reports 2023 Second Quarter Financial Results

Retrieved on: 
Thursday, August 10, 2023
Operating cost, International, Abbott, CE marking, Magic, Documentation, Average cost, Ecosystem, Robotics, NYSE, Video game, Bank, Stereotaxis

ST. LOUIS, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the second quarter ended June 30, 2023.

Key Points: 
  • ST. LOUIS, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the second quarter ended June 30, 2023.
  • System revenue for the quarter was $3.3 million and recurring revenue was $4.6 million, compared to $0.6 million and $5.6 million in the prior year second quarter, respectively.
  • Gross margin for the second quarter of 2023 was 53% of revenue.
  • Excluding non-cash stock compensation expense, adjusted operating expenses in the current quarter were $6.9 million compared to $7.2 million for adjusted operating expenses in the prior year second quarter.

Stereotaxis and Abbott Combine Technologies in First Integrated Procedures to Treat Arrhythmia Patients

Retrieved on: 
Tuesday, July 18, 2023
Workflow, Erasmus MC, Heart Rhythm, Patient, Physician, Electrophysiology, Arrhythmia, Robotics, NYSE, Safety, Medical imaging, Medical device, Stereotaxis

The combination of Abbott’s leading cardiac mapping system with Stereotaxis’ advanced robotic technology brings together highly detailed real-time diagnostic information with the unprecedented precision and stability of robotics during therapy delivery.

Key Points: 
  • The combination of Abbott’s leading cardiac mapping system with Stereotaxis’ advanced robotic technology brings together highly detailed real-time diagnostic information with the unprecedented precision and stability of robotics during therapy delivery.
  • The integration of these technologies was announced at Heart Rhythm 2023.
  • “The integration of both systems enables me to address the most complex arrhythmia patients.
  • I am very pleased with this technological advance and the growing recognition that robotics plays an important role for the electrophysiology field.”

Stereotaxis to Initiate First-in-Human Trial to Support CE Mark Application of MAGiC Catheter

Retrieved on: 
Thursday, June 15, 2023
CE marking, Notified body, NYSE, Magic, Patient, Regulation, Electrophysiology, Medical device, Stereotaxis

ST. LOUIS, June 15, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it intends to initiate a first-in-human trial to support the CE Mark submission for its MAGiC™ catheter.

Key Points: 
  • ST. LOUIS, June 15, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it intends to initiate a first-in-human trial to support the CE Mark submission for its MAGiC™ catheter.
  • Stereotaxis’ MAGiC catheter is a robotically-navigated magnetic ablation catheter designed to perform minimally invasive cardiac ablation procedures.
  • The catheter’s CE Mark submission was made in July 2022 and included substantial in vivo preclinical, lab and bench data.
  • Stereotaxis intends to complete a first-in-human study to support the MAGiC submission before the end of this year.

Stereotaxis and Abbott Announce Global Collaboration Combining Leading Mapping and Robotic Technologies to Improve Treatment of Abnormal Heart Rhythms

Retrieved on: 
Friday, May 19, 2023
Field line, Heart failure, Arrest, Stroke, Medicine, Arrhythmia, Robotic magnetic navigation, Banner University Medical Center Tucson, US, Patient, Physician, Electrophysiology, Risk, Robotics, NYSE, US FDA, Safety, Medical device, Stereotaxis

ST. LOUIS, May 19, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS) today announced a global collaboration with Abbott (NYSE: ABT) to integrate Abbott’s EnSite™ X EP System with Stereotaxis’ Robotic Magnetic Navigation systems.

Key Points: 
  • ST. LOUIS, May 19, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS) today announced a global collaboration with Abbott (NYSE: ABT) to integrate Abbott’s EnSite™ X EP System with Stereotaxis’ Robotic Magnetic Navigation systems.
  • The combination of Abbott’s leading cardiac mapping system with Stereotaxis’ advanced robotic technology brings together highly detailed real-time diagnostic information with the unprecedented precision and stability of robotics during therapy delivery.
  • Technology integration enhances the physician experience, streamlines procedural workflow, and supports the improved treatment of patients with abnormal heart rhythms.
  • Stereotaxis and Abbott have successfully completed integration of their technologies and performed testing demonstrating joint compatibility.

Stereotaxis Reports 2023 First Quarter Financial Results

Retrieved on: 
Tuesday, May 9, 2023
Operating cost, CE marking, Ecosystem, IDE, International, FDA, Magic, Research, Investment, NYSE, Average cost, Video game, Stereotaxis

ST. LOUIS, May 09, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the first quarter ended March 31, 2023.

Key Points: 
  • ST. LOUIS, May 09, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the first quarter ended March 31, 2023.
  • System revenue for the first quarter was $1.8 million and recurring revenue was $4.7 million, compared to $1.6 million and $5.4 million in the prior year first quarter, respectively.
  • At March 31, 2023, Stereotaxis had cash and cash equivalents, including restricted cash, and investments of $26.8 million and no debt.
  • Stereotaxis reiterates its expectation of double-digit revenue growth in 2023 driven by revenue recognition of system backlog and new system orders.